Letters by company
Evolution AB (publ)
4 letters discussing EVGGF. Everything written about it on this site is on its ticker page.
- Protean Funds Wide Confidence Intervals Protean Funds argues that position sizing should assume investors will sometimes be confidently wrong, after profit warnings at RaySearch and Devyser. Small Cap added to Devyser, rebuilt MT Højgaard and increased real-estate exposure while trimming Truecaller. Select traded Evolution, shorted Industrivärden and added to its Novo Nordisk short after the ZEUS readout. July 2026 DVYSR $89MEVGGF $15BNVO $168B
- Broyhill Asset Management The Broyhill Letter 2024.Q4 Broyhill attributes its lagging value strategy to market concentration in US growth stocks and reinforces allocations to cheaper European, smaller-cap and defensive businesses. It argues for NICE, Evolution, Six Flags, Baxter and Avantor, while adding Charles River Labs and citing valuation dislocations, operational recoveries and durable earnings potential. 2024 AVTR $11BBAX $13BEVGGF $15B
- Broyhill Asset Management The Broyhill Letter 2024.Q3 Broyhill initiated Rentokil Initial, Evolution AB and Nice Ltd, citing consolidation potential, online-gaming legalization, and AI-enabled cloud contact-center software. It exited Danone, PayPal and EPAM Systems over valuation, unclear product growth and changing labor-force risks, while maintaining its theses on Philip Morris and Baxter. Q3 2024 BAX $13BDANOY $42BDG $26B
- Broyhill Asset Management The Broyhill Letter 2026 Q1 Broyhill attributes the quarter’s shortfall to its lack of energy exposure, overseas holdings and defensive-sector positions, while arguing that portfolio companies’ fundamentals remain intact. It sold Ball, Kenedy Wilson, Fresenius Medical Care, Evolution and Avantor, and added Microsoft, Smurfit WestRock, Sotera Health, Masco and Floor and Décor amid dislocations. 2026.Q1 IQV $42BAVTR $11BBALL $15B
